Post-earnings recap
Reported
Thu, Nov 1, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Corcept Therapeutics reported a positive EPS surprise, which contributed to a 4.09% increase in stock price. The management's focus on pipeline advancement suggests they are prioritizing long-term growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.22 | N/A | +2.01% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—